Hamilton, Ontario, September 8, 2020 – Isotopia Molecular Imaging and CPDC are pleased to announce that they have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer, including neuroendocrine tumors and prostate cancer.
The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, will produce n.c.a. Lu-177 in collaboration with Isotopia Molecular Imaging for distribution in North America.
n.c.a. Lu-177 is used in Targeted Radionuclide Therapy in the field of Precision Oncology. By binding n.c.a. Lu-177 isotopes to tumor-specific targeting molecules, the resulting radiopharmaceutical targets the tumor and delivers precise cell-killing radiation that spares normal healthy tissue. Isotopia has developed a reliable and unique GMP method to produce a highly pure form of Lu-177. n.c.a. Lu-177 contains no Mercury (Hg) and no metastable Lu-177m, therefore there is no need for cost intensive clinical waste management.
Isotopia’s CEO & Co-Founder Dr. Eli Shalom stated “The CPDC manufacturing site is the first step towards Isotopia’s global footprint plan to ensure efficient production of n.c.a. Lu-177 and will be added to its existing Drug Master File (DMF). CPDC’s strategic location in Southern Ontario along with its professional and enthusiastic personnel, renowned expertise in logistics and just-in-time delivery will enhance distribution of Isotopia’s n.c.a. Lu-177 and secure supply for our radiopharmaceutical and CMO clients in North America.”
Isotopia and CPDC intend to expand their partnership to include commercial-scale production of n.c.a. Lu-177 at CPDC’s subsidiary NuGeneris Specialty Pharmaceuticals Inc. to meet future commercial market demand. NuGeneris is a global commercial stage radiopharmaceutical manufacturing service provider.
“As a global leader specializing in radiopharmaceutical research, development and manufacturing, we recognize the importance of a stable and reliable supply of medical isotopes for manufacturing of life-altering therapies” said Justyna Kelly, CEO of CPDC. “We are looking forward to bringing this process to CPDC, which will facilitate access to n.c.a. Lu-177 for our clients and for our pipeline.” Ms. Kelly added. “CPDC and Isotopia are aligned in a common vision and we are very excited about this partnership.”
In addition to production of n.c.a. Lu-177, Isotopia and CPDC have also committed to collaborate on the development of GMP manufacturing processes for other emerging medical isotopes.
About the Centre for Probe Development and Commercialization
The Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and The Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a pipeline of products along with a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca.
Isotopia Molecular Imaging Ltd. is a collaboration between The Metrontario Group and Israel’s leading scientists in the field of radiopharmaceuticals. The Isotopia development team is a multidisciplinary team consisting of nuclear pharmacists, radiochemists, nuclear engineers and physicists.
The experienced Isotopia team, together with its nuclear pharmacy, cyclotron facility, Lu-177 production site and sterile manufacturing plant, are a well-established platform for development. Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy. For more information about Isotopia, please visit: www.isotopia.co.il.
Isotopia Molecular Imaging Ltd.
Tel: (972)-3-9130314 ,KMoshkoviz@isotopia.co.il,
Centre for Probe Development and Commercialization
905 525-9140, ext. 21212 ,email@example.com
Hamilton, Ontario (October 22, 2020) ‐ Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the Company’s Board of Directors has appointed Bruno Paquin as Interim Chief Executive Officer, effective November 2, 2020. Justyna Kelly, CPDC’s outgoing CEO said, “Since joining CPDC,
If you are an academic researcher or a biotech company looking to pave the road to successful commercialization of your radiopharmaceutical innovation, join us on October 15th, 2020. What is CARI? CARI is a collaboration between The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) where we will bring respective resources together to
The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) are pleased to announce they have formed a new collaboration, “The CPDC-adMare Radiopharmaceutical Initiative (CARI)” to bring their respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain a considerable global competitive advantage: radiopharmaceuticals. This